NCT06738433View on ClinicalTrials.gov

Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions
Constipation
Interventions
DIETARY_SUPPLEMENT

ABB i5

Prebiotic ABB i5 (NextDext®, 5g)

DIETARY_SUPPLEMENT

ABB C24

ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g

Trial Locations (1)

08030

Isabel Roig, Barcelona

Sponsors

Lead Sponsor

AB Biotek
All Listed Sponsors
collaborator

Grupo Colisée

UNKNOWN

lead

AB Biotek

INDUSTRY

NCT06738433 - Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial | Biotech Hunter | Biotech Hunter